PharmaCyte Biotech Reports Strong Cash and Asset Position
Key Highlights
- ➤Cash and equivalents $17.7 million as of July 31, 2026
- ➤Total assets approximately $36.7 million, including cash and equivalents
- ➤Stockholders’ equity approximately $27.5 million as of July 31, 2026
- ➤Approximately 566,000 common shares outstanding
Expert Statements
Josh Silverman, Chief Executive Officer of PharmaCyte Biotech
“Our balance sheet is the foundation of PharmaCyte’s strategy. With $17.7 million in cash and more than $36 million in total assets, we have the capital to deploy with discipline and to pursue opportunities designed to create value for our shareholders.”
As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) today provided an update on its financial position. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB’s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including approximately $17.7 million in cash and cash equivalents. Stockholders’ equity totaled approximately $27.5 million as of July 31, 2026. PharmaCyte has approximately 566,000 shares of common stock outstanding.
Get started
Create a free account to read the full story.